Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same author

Oncology Organization and Oncologist Networks Under Medicare Advantage Plans.

JAMA network open·2026
Same author

Trajectories of antidepressant dispensing among privately insured transgender people in the United States.

Scientific reports·2026
Same author

Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data.

Endocrine·2026
Same author

Federal housing assistance, cancer care, and overall survival among older adults with prostate cancer.

Journal of the National Cancer Institute·2026
Same author

Impacts of Hurricane-Related Flooding on Time to Initial Cancer-Directed Treatment in North Carolina.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Related Experiment Video

Updated: May 27, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

Identifying specific chemotherapeutic agents in Medicare data: a validation study.

Jennifer L Lund1, Til Stürmer, Linda C Harlan

  • 1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. jlund@email.unc.edu

Medical Care
|November 15, 2011
PubMed
Summary
This summary is machine-generated.

Medicare claims can identify chemotherapy receipt in elderly cancer patients, though accuracy varies by drug and administration method. This is crucial for understanding real-world cancer treatment effectiveness.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Experiment Videos

Last Updated: May 27, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Area of Science:

  • Oncology
  • Health Services Research
  • Biostatistics

Background:

  • Large health care databases are vital for studying chemotherapy in real-world practice, especially for elderly patients often excluded from clinical trials.
  • Accurate identification of chemotherapy is essential to avoid bias in estimates of treatment frequency, benefits, and harms.

Purpose of the Study:

  • To assess the validity of Medicare claims for identifying chemotherapy receipt in elderly patients with colorectal, breast, lung, and ovarian cancers.
  • To compare Medicare claims data against the National Cancer Institute's Patterns of Care (POC) studies, considered the gold standard.

Main Methods:

  • Compared linked Medicare claims with POC data for 2-12 months postdiagnosis in elderly patients with specific cancer types.
  • Calculated κ, sensitivity, specificity, and predictive values to evaluate the accuracy of Medicare claims in identifying chemotherapy receipt and specific agents.

Main Results:

  • Medicare claims demonstrated high sensitivity and specificity for identifying overall chemotherapy receipt across all cancer sites.
  • Validity varied significantly by specific chemotherapy agent, cancer site, and administration route (oral vs. intravenous).
  • Oral capecitabine showed high specificity (98%) but low sensitivity (47%), while intravenous oxaliplatin had higher sensitivity (75%) and similar specificity (97%).

Conclusions:

  • Medicare claims are a reliable tool for identifying chemotherapy receipt, particularly for intravenous agents, with improved accuracy compared to previous studies.
  • Ongoing research should focus on newly approved agents and the influence of Medicare Part D coverage decisions on treatment patterns.